Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,152 | 3 | 95.8% |
| Food and Beverage | $93.60 | 1 | 4.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $2,152 | 3 | $0 (2024) |
| Stryker Corporation | $93.60 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,103 | 1 | F. Hoffmann-La Roche AG ($1,103) |
| 2023 | $1,049 | 2 | F. Hoffmann-La Roche AG ($1,049) |
| 2018 | $93.60 | 1 | Stryker Corporation ($93.60) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,102.96 | Research |
| Study: Tenecteplase in stroke patients between 4 5 and 24 hours | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $686.96 | Research |
| Study: Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III TIMELESS Trial | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.30 | Research |
| Study: EFFICACY AND SAFETY OF TENECTEPLASE IN PATIENTS WITH LATE-WINDOW ACUTE ISCHEMIC STROKE AND EVIDENCE OF SALVAGEABLE TISSUE: RESULTS FROM THE PHASE 3 TIMELESS TRIAL | ||||||
| 01/25/2018 | Stryker Corporation | NEUROFORM EZ (Device) | Food and Beverage | Cash or cash equivalent | $93.60 | General |
| Category: STENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Tenecteplase in stroke patients between 4 5 and 24 hours | F. Hoffmann-La Roche AG | $1,103 | 1 |
| Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III TIMELESS Trial | F. Hoffmann-La Roche AG | $686.96 | 1 |
| EFFICACY AND SAFETY OF TENECTEPLASE IN PATIENTS WITH LATE-WINDOW ACUTE ISCHEMIC STROKE AND EVIDENCE OF SALVAGEABLE TISSUE: RESULTS FROM THE PHASE 3 TIMELESS TRIAL | F. Hoffmann-La Roche AG | $362.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 487 | 1,049 | $313,026 | $103,706 |
| 2022 | 9 | 509 | 995 | $300,922 | $96,963 |
| 2021 | 8 | 392 | 598 | $181,013 | $60,183 |
| 2020 | 8 | 384 | 680 | $194,951 | $65,175 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 117 | 629 | $171,612 | $61,054 | 35.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 151 | 154 | $71,939 | $21,659 | 30.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 49 | 51 | $14,019 | $4,786 | 34.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 37 | $10,578 | $2,803 | 26.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $9,969 | $2,692 | 27.0% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2023 | 23 | 23 | $7,647 | $2,337 | 30.6% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 19 | 19 | $5,769 | $1,845 | 32.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 23 | $6,944 | $1,764 | 25.4% |
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 12 | 12 | $5,286 | $1,692 | 32.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 26 | $4,783 | $1,679 | 35.1% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 23 | 56 | $4,480 | $1,395 | 31.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 122 | 602 | $151,704 | $50,034 | 33.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 137 | 137 | $67,132 | $21,774 | 32.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 46 | 46 | $22,086 | $6,735 | 30.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 50 | $13,220 | $3,715 | 28.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 39 | 39 | $10,143 | $3,359 | 33.1% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 37 | 42 | $9,366 | $3,093 | 33.0% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 23 | 23 | $6,982 | $2,248 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $6,477 | $1,808 | 27.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 19 | $5,194 | $1,459 | 28.1% |
| G0426 | Telehealth consultation, emergency department or initial inpatient, typically 50 minutes communicating with the patient via telehealth | Office | 2022 | 13 | 13 | $4,336 | $1,424 | 32.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 11 | 11 | $4,282 | $1,313 | 30.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 101 | 294 | $73,768 | $24,652 | 33.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 95 | 96 | $46,914 | $15,680 | 33.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 44 | 44 | $19,906 | $6,533 | 32.8% |
About Dr. Wayne Clark, MD
Dr. Wayne Clark, MD is a Neurology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356357958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Wayne Clark, MD has received a total of $2,246 in payments from pharmaceutical and medical device companies, with $1,103 received in 2024. These payments were reported across 4 transactions from 2 companies. The most common payment nature is "" ($2,152).
As a Medicare-enrolled provider, Clark has provided services to 1,772 Medicare beneficiaries, totaling 3,322 services with total Medicare billing of $326,026. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Portland, OR
- Active Since 08/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1356357958
Products in Payments
- NEUROFORM EZ (Device) $93.60
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Portland
Kyle Smoot, M.d, M.D
Neurology — Payments: $944,765
Stanley Cohan, M.d, M.D
Neurology — Payments: $664,935
Dr. Chafic Karam, M.d, M.D
Neurology — Payments: $647,064
Dr. John Dolan, D.o, D.O
Neurology — Payments: $550,588
Kiren Kresa-Reahl, M.d, M.D
Neurology — Payments: $421,575
Matthew Brodsky, Md, MD
Neurology — Payments: $244,252